Biopharmaceutical Neurodegenerative Disease Therapies sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Biopharmaceutical Neurodegenerative Disease Therapies
1.1 - About Biopharmaceutical Neurodegenerative Disease Therapies sector
Companies in Biopharmaceutical Neurodegenerative Disease Therapies discover, develop, and commercialize treatments for CNS disorders such as Alzheimer’s, Parkinson’s, ALS, and Huntington’s disease. They advance disease‑modifying and symptomatic drugs across preclinical and clinical stages, aiming to slow progression, improve function, and extend quality of life. Their value lies in differentiated mechanisms, validated biomarkers, and scalable manufacturing that support regulatory approval, market access, and partnerships with larger pharma.
Typical offerings span monoclonal antibodies targeting amyloid and tau, small‑molecule kinase and protease inhibitors, antisense oligonucleotides to modulate gene expression, and AAV‑based gene therapies for rare neurodegenerative mutations. Many also provide symptomatic agents such as dopamine modulators and neuroprotective compounds, plus CNS‑targeted delivery technologies to cross the blood–brain barrier. Integrated capabilities include biomarker assays, digital and imaging endpoints, translational models, CMC and GMP manufacturing, and global clinical development operations.
Primary customers include neurology clinics and hospital systems, specialty pharmacies and payers, as well as larger biopharma strategic buyers seeking in‑licensing or acquisitions. These companies help expand treatment options, accelerate trial timelines and regulatory approvals, improve patient outcomes and adherence, and diversify partner pipelines with differentiated assets. They also enable broader market access through evidence generation, health‑economics data, and scalable supply chains for complex biologics and CNS formulations.
2. Buyers in the Biopharmaceutical Neurodegenerative Disease Therapies sector
2.1 Top strategic acquirers of Biopharmaceutical Neurodegenerative Disease Therapies companies
Alector
- Description: Provider of biotechnology research and clinical-stage therapies targeting neurodegenerative diseases, developing antibody-based and protein-engineering candidates that remove toxic proteins, replace deficient proteins and restore immune and neuronal function, leveraging genetically validated targets and its proprietary Alector Brain Carrier blood-brain barrier technology.
- Key Products:
- Therapeutic Candidate Pipeline: Pipeline of first- and best-in-class therapeutic candidates that remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function in neurodegenerative disorders
- Alector Brain Carrier (ABC) technology: Proprietary ABC technology for blood-brain barrier transport, enabling efficient delivery of antibodies and engineered proteins directly to brain tissue for enhanced therapeutic efficacy
- Protein Engineering & Antibody Discovery Expertise: In-house protein engineering and antibody discovery capabilities generate novel, highly specific molecules that target neurodegenerative disease pathways, accelerating development of transformative immuno-neurology therapies
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Biopharmaceutical Neurodegenerative Disease Therapies sector
M&A buyer group 1: Neurology
Lundbeck
- Type: N/A
- Employees: ●●●●●
- Description: Provider of pharmaceutical contract development and manufacturing services specializing in solid-dosage drug products, offering end-to-end development, clinical and commercial batch production, analytical, packaging and supply-chain support from ISO-certified sites in Denmark and France.
- Key Products:
- Contract Development & Manufacturing (CDM): Provides formulation development, clinical and commercial solid-dosage production plus integrated packaging using advanced facilities in Denmark and France, enabling rapid time-to-market
- Analytical Services: Operates fully equipped laboratories delivering comprehensive testing and regulatory-compliant analytical support throughout product lifecycle to ensure quality and safety
- Supply Chain Services: Manages storage and global shipping, including controlled narcotic and psychotropic products, ensuring continuous availability and full regulatory compliance for customers
- Quality & HSE Management: Implements ISO 14001 and ISO 45001 certified quality, safety and environmental systems that safeguard high manufacturing standards and operational excellence across all activities.
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Biopharmaceutical Neurodegenerative Disease Therapies sector
3.1 - Buyout funds in the Biopharmaceutical Neurodegenerative Disease Therapies sector
2.2 - Strategic buyer groups for Biopharmaceutical Neurodegenerative Disease Therapies sector
4 - Top valuation comps for Biopharmaceutical Neurodegenerative Disease Therapies companies
4.2 - Public trading comparable groups for Biopharmaceutical Neurodegenerative Disease Therapies sector
Valuation benchmark group 1: Small-Molecule Pharmaceutical Manufacturing Companies
Eli Lilly
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of innovative medicines and biotechnology solutions aimed at improving global health. Utilizes advanced scientific research and development to create treatments for various medical conditions, enhancing quality of life and addressing unmet clinical needs in diverse healthcare areas.
- Key Products:
- Insulin Access Programs: Solutions to provide accessible insulin treatments for diabetes management.
- Cancer Treatments: Medicines targeted at oncology to improve patient outcomes.
- Cardiovascular Treatments: Innovative treatments for heart-related conditions.
- Immunology: Solutions addressing autoimmune diseases and enhancing immune system health.
- Neuroscience: Medications to treat neurological disorders including Alzheimer's and schizophrenia.